Annovis Bio (ANVS)
(Delayed Data from NYSE)
$12.16 USD
-0.95 (-7.25%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $12.49 +0.33 (2.71%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.16 USD
-0.95 (-7.25%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $12.49 +0.33 (2.71%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum C VGM
Zacks News
Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan
by Zacks Equity Research
Pacira (PCRX) gains upon the inclusion of Exparel as one of only six qualifying non-opioid drugs to treat postsurgical pain in the proposed reimbursement rule, if adopted.
Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK
by Zacks Equity Research
Inovio (INO) soars 19% as its lead candidate, INO-3107, receives the innovative medicine tag under the U.K.'s Innovative Licensing and Access Pathway to treat recurrent respiratory papillomatosis.
Brookdale Senior (BKD) Q2 Occupancy Jumps, Growth Trend Persists
by Zacks Equity Research
Brookdale Senior's (BKD) weighted average occupancy for June rises 140 bps year over year.
uniQure (QURE) Soars on New Huntington's Disease Study Data
by Zacks Equity Research
uniQure (QURE) surges 77% on updated positive interim data from 29 treated patients in the ongoing phase I/II studies of investigational gene therapy, AMT-130, for Huntington's disease.
IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data
by Zacks Equity Research
IDEAYA (IDYA) gains 15% on positive clinical data from its phase II study evaluating the 30 mg monotherapy expansion dose of IDE397 to treat MTAP-deletion urothelial and NSCLC patients.
Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag
by Zacks Equity Research
Adicet (ACET) gains as the FDA grants the Fast Track designation to ADI-270 for the potential treatment of a form of kidney cancer. A phase I study for this indication is set to begin in 2024.
Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study
by Zacks Equity Research
Annovis (ANVS) surges 76% on Jul 2 after meeting the primary and secondary goals with statistical significance in the late-stage PD study of its lead candidate, buntanetap.
Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug
by Zacks Equity Research
Apellis (APLS) declines as CHMP issues a second negative opinion for the approval of intravitreal pegcetacoplan to treat GA in the EU. The company plans to seek re-examination of the same.
PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug
by Zacks Equity Research
PTC Therapeutics (PTCT) falls as the EC's advisory committee adopts a negative opinion regarding the renewal of the conditional marketing approval of Translarna to treat nmDMD in the EU.
Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting
by Zacks Equity Research
Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.
Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote
by Zacks Equity Research
Merck's (MRK) vaccine, Capvaxive, gets unanimous recommendation by a CDC committee for adults aged 65 years and older for pneumococcal vaccination and those with certain other underlying conditions.
Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug
by Zacks Equity Research
Dr. Reddy's (RDY) is set to acquire Haleon's leading global NRT brand, Nicotinell, and its related portfolio across all formats of the drug for GBP 500 million to boost its OTC presence worldwide.
Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal
by Zacks Equity Research
Novo Nordisk (NVO) declines as a late-stage study of its uncontrolled hypertension and advanced chronic kidney disease candidate, ocedurenone, fails to achieve the primary goal.
CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business
by Zacks Equity Research
CASI Pharmaceuticals (CASI) gets a proposal letter from its chairman for acquiring its business operations in China. Its shares rise on the news.
Bayer's (BAYRY) AskBio Advances Parkinson Disease Study
by Zacks Equity Research
Bayer's (BAYRY) wholly owned and independently operating subsidiary AskBio started recruitment in the phase II study for Parkinson's disease.
ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why
by Zacks Equity Research
ImmunityBio (IBRX) rises 17% in the past week as it announces insurance coverage as well as the treatment of the first patients with its newly approved bladder cancer immunotherapy, Anktiva.
Novo Nordisk (NVO) to Invest $4.1B in Clayton Facility Expansion
by Zacks Equity Research
Novo Nordisk (NVO) plans to invest $4.1 billion in order to expand its Clayton facility with a second manufacturing plant, boosting capacity for injectable treatments and creating 1,000 new jobs.
Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals
by Zacks Equity Research
Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy, achieves primary and all secondary endpoints.
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
by Zacks Equity Research
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals
by Zacks Equity Research
JAZZ shares are down 5% as it fails to achieve statistical significance on the primary and key secondary endpoint in a mid-stage tremor study on suvecaltamide.
Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?
by Zacks Equity Research
Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.
Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up
by Zacks Equity Research
Day One (DAWN) gains 11% on in-licensing exclusive worldwide rights to MabCare???s MTX-13, which is set to begin clinical studies for adult and pediatric solid tumor indications.
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
by Zacks Equity Research
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals
by Zacks Equity Research
Aerovate's (AVTE) shares plunge 93% as its lead candidate, AV-101, fails to meet the primary and secondary endpoints in the phase IIb/III study to treat pulmonary arterial hypertension patients.
Amgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment
by Zacks Equity Research
Amgen's (AMGN) Blincyto is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-ALL in the consolidation phase, regardless of MRD status.